This study is part of a major drug development program to evaluate the prevention and treatment of dyslipidemia, atherosclerosis, and coronary heart disease.
Pacific will provide the sponsor with cholesterol, lipid, inflammatory and oxidative marker testing on samples collected to support the sponsor’s clinical trial.
Testing is anticipated to begin in September 2006 and will continue for about 18 months. Pacific said that it estimates total revenue over the expected life of this contract to reach approximately $1.2 million.
“The cholesterol and inflammatory marker profile requires a central laboratory that has expertise in biomarkers for both lipids and cardiovascular risk, and PBI is well positioned to deliver the highest quality results in both of these areas,” said Ron Helm, CEO of Pacific.